GLIMEPIRIDE — ASSISTANT TESTED BY TIME

Authors

  • Orlyk О. S. Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine; SSI «Center for Innovative Medical Technologies of the NAS of Ukraine», Kiev, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2019.3.16

Keywords:

diabetes mellitus, glimepiride, diet, physical activity

Abstract

The article highlights the current approaches to the treatment and criteria for compensation of diabetes, based on new international recommendations. Much attention is paid to nutrition, lifestyle modification, education and patient self-control, as the basis for successful treatment of diabetes. A review of clinical studies in which were studied the glucose lowering ability of glimepiride, the effect on insulin resistance, the processes of atherogenesis, and the protective effect on the vascular wall were presented.

References

IDF. Diabetes Atlas. 8th ed. 2017.

The Emerging Risk Factors Collaboration. JAMA 2015; 314: 52.

Dedov II, Shestakova MV. Saharnyj diabet, Moskva, 2003: 304-318.

Vlasenko MV, Man’kovs’kyj BM. Taktyka vedennja hvoryh na cukrovyj diabet : posib. dlja endokrynologiv, Kyi’v, 2018: 7-36.

Davis SN. J Diab Complications 2004; 18(6): 367-376. https://doi.org/10.1016/j.jdiacomp.2004.07.001.

Leibel B. Can Med Assoc J 1971; 105(3): 292-294.

Campbell RK. Ann Pharmacother 1 998; 3 2(10): 1044-1052.

Ashcroft FM, Gribble FM. Diabetologia 1999; 42(8): 903-919.

N Engl J Med 1993; 329(14): 977-986.

Stratton IM, Adler AI, Neil HA, et al. BMJ 2000;321: 405-412. https://doi.org/10.1136/bmj.321.7258.405.

Korytkowski M, Thomas A, Reid L, et al. Diabetes Care 2002; 25(9): 1607-1611. https://doi.org/10.2337/diacare.25.9.1607.

Schade DS, Jovanovic L, Schneider J. J Clin Pharmacol 1998; 38(7): 636-641.

Goldberg RB, Holvey SM, Schneider J. Diabetes Care 1996; 19(8): 849-856.

Rosenstock J, Samols E, Muchmore DB, Schneider J. Diabetes Care 1996; 19(11): 1194-1199.

Muller G, Satoh Y, Geisen K. Diabetes Res Clin Pract 1995; 28(1): S115-S137.

Haupt A, Kausch C, Dahl D, et al. Diabetes Care 2002; 25(12): 2129-2132. https://doi.org/10.2337/diacare.25.12.2129.

Rosak C. J Diab Complications 2002; 16: 123-132.

Overkamp D, Volk A, Maerker E, et al. Diabetes Care 2002; 25(11): 2065-2073.

Xu DY, Zhao SP, Huang QX, et al. Diabetes Res Clin Pract 2010; 88(1): 71-75. https://doi.org/10.1016/j.diabres.2009.12.010.

Draeger KE, Wernicke-Panten K, Lomp HJ, et al. Horm Metab Res 1996; 28(9): 419-425.

Muller G. Mol Med 2000; 6(11): 907-933.

Tsunekawa T, Hayashi T, Suzuki Y, et al. Diabetes Care 2003; 26(2): 285-289. https://doi.org/10.2337/diacare.26.2.285.

Kishida K, Funahashi T, Shimomura I. Endocr Metab Immune Disord Drug Targets 2012; 11.

Reiner Z, Catapano AL, De Backer G, et al. Eur Heart J 2011; 32(14): 1769-1818. https://doi.org/10.1093/eurheartj/ehr158.

Muller G, Wied S, Straub J, Jung C. Eur J Pharmacol 2008; 597(1-3): 6-18. https://doi.org/10.1016/j.ejphar.2008.08.034.

Shakuto S, Sato Y, Ohshima K, Yaguchi M. J Diab Complications 2001; 15(1): 68.

Hink U, Li H, Mollnau H, et al. Circ Res 2001; 88(2): E14-E22.

Ageev FT. Serdechnaja Nedostatochnost’ 2003; (4): 22.

Durand E, Scoazec A, Lafont A, et al. Circulation 2004; 109(21): 2503-2506. https://doi.org/10.1161/01.CIR.0000130172.62481.90.

Salani B, Repetto S, Cordera R, Maggi D. Biochem Biophys Res Commun 2005; 335: 832-835.

Ueba H, Kuroki M, Hashimoto S, et al. Atherosclerosis 2005; 183(1): 35-39. https://doi.org/10.1016/j.atherosclerosis.2005.01.055.

Jojima T, Suzuki K, Hirama N, et al. Diabetes Obes Metab 2009; 11(2): 143-149. https://doi.org/10.1111/j.1463-1326.2008.00923.x.

Sharma SC. J Pathol 1981; 4: 501-503.

Aso Y. Front Biosci 2007; 12: 2957-2966.

Dills DG, Schneider J. Horm Metab Res 1 996; 2 8(9): 426-429.

Holstein A, Plaschke A, Egberts EH. Diabetes Metab Res Rev 2001; 17(6):467-473.

Nathan DM, Buse JB, Davidson MB, et al. Diabetes Care 2009; 32(1): 193-203. https://doi.org/10.2337/dc08-9025.

Downloads

Published

2019-08-28

How to Cite

Orlyk О. S. (2019). GLIMEPIRIDE — ASSISTANT TESTED BY TIME. Problems of Endocrine Pathology, 69(3), 121-127. https://doi.org/10.21856/j-PEP.2019.3.16